However, L-BLP25 (Stimuvax), a liposome-based vaccine with MUC1-N terminal repeats, failed to improve overall survival in phase III trial for unresectable stage III NSCLC (71, 72). Here, MUC1 is linked to non-small cell lung carcinoma.